Abstract | Gastritis kao bolest modernoga doba i širokom rasprostranjenošću diljem svijeta svakako zaslužuje
pažnju. On predstavlja veliki javno zdravstveni problem ne samo zbog posljedične hospitalizacije i
povećanja troškova liječenja, već i zbog smanjene kvalitete života pacijenta. Velik je napredak
postignut u definiciji i terapiji gastritisa od otkrića bakterije H. pylori 1982. godine do danas.
Liječenje infekcije H. pylori provodi se kombinacijom IPP-a, makrolida i beta laktamskog
antibiotika. Neuspjeh je najčešće povezan s rezistencijom, a ne s reinfekcijom. IPP su visoko
efektivni lijekovi čije nuspojave dugoročne primjene moramo temeljito istražiti. Potreban je
individualan pristup za svakoga pacijenta te pažljiv i svrsishodan izbor terapije. Uz farmakološke
mjere ne smijemo zaboraviti i ne farmakološke mjere koje su jednako važne i služe kao nadopuna.
Ulaganjem u znanost i nova istraživanja povećavamo razumijevanje bolesti i problema koje ona
nosi. Iskrena znatiželja, potraga za istinom i dobrobit pacijenta neka budu naši glavni motivatori. |
Abstract (english) | Gastritis, being a widespread illness of the modern era, certainly deserves our attention. It
represents a serious public healthcare problem, because of not only the consequent hospitalization
and increased healthcare expenses, but also because it reduces the life quality of those afflicted.
Since the initial discovery of the H. pylori bacteria in 1982, there has been significant
progress in the definition and treatment of Gastritis. The infection caused by the H. pylori bacteria
is treated with a combination of Proton pump inhibitors (PPIs), macrolides and β-lactam
antibiotic, unsuccessful treatment usually being a result of patient resistance, rather than reinfection.
PPIs are highly effective drugs whose side effects are yet to be thoroughly examined, keeping in
mind the necessity of an individual approach for each patient, as well as a mindful choice of
appropriate therapy. In addition to pharmacological measures, we should not neglect equally
important non-pharmacological measures, which can be additionally helpful. By investing in new
scientific research, we can help raise awareness about this illness and its resulting problems. Honest
curiosity, the search for truth, as well as the well-being of our patients, should be our main
motivators moving forward. |